-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Alpha Teknova (NASDAQ:TKNO) Versus Achieve Life Sciences (NASDAQ:ACHV) Head-To-Head Contrast
Alpha Teknova (NASDAQ:TKNO) Versus Achieve Life Sciences (NASDAQ:ACHV) Head-To-Head Contrast
Alpha Teknova (NASDAQ:TKNO – Get Rating) and Achieve Life Sciences (NASDAQ:ACHV – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
Profitability
This table compares Alpha Teknova and Achieve Life Sciences' net margins, return on equity and return on assets.
Get Alpha Teknova alerts:| Net Margins | Return on Equity | Return on Assets | |
| Alpha Teknova | -86.67% | -16.09% | -12.24% |
| Achieve Life Sciences | N/A | -240.36% | -104.96% |
Valuation & Earnings
This table compares Alpha Teknova and Achieve Life Sciences' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Teknova | $36.89 million | 4.64 | -$9.80 million | ($1.35) | -4.52 |
| Achieve Life Sciences | N/A | N/A | -$33.15 million | ($3.99) | -1.18 |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Alpha Teknova and Achieve Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Teknova | 0 | 0 | 1 | 0 | 3.00 |
| Achieve Life Sciences | 0 | 0 | 2 | 0 | 3.00 |
Alpha Teknova currently has a consensus target price of $9.33, indicating a potential upside of 53.01%. Achieve Life Sciences has a consensus target price of $17.33, indicating a potential upside of 268.01%. Given Achieve Life Sciences' higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Alpha Teknova.
Institutional and Insider Ownership
22.7% of Alpha Teknova shares are owned by institutional investors. Comparatively, 21.1% of Achieve Life Sciences shares are owned by institutional investors. 15.2% of Alpha Teknova shares are owned by insiders. Comparatively, 1.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Alpha Teknova has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
Summary
Alpha Teknova beats Achieve Life Sciences on 7 of the 12 factors compared between the two stocks.
About Alpha Teknova
(Get Rating)
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
About Achieve Life Sciences
(Get Rating)
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
Alpha Teknova (NASDAQ:TKNO – Get Rating) and Achieve Life Sciences (NASDAQ:ACHV – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
納斯達克：TKNO-GET評級)和成就生命科學(納斯達克：ACHV-GET評級)都是小盤醫療公司，但哪隻股票更具優勢？我們將根據兩家公司的股息、收益、風險、估值、分析師建議、盈利能力和機構持股情況對它們進行比較。
Profitability
盈利能力
This table compares Alpha Teknova and Achieve Life Sciences' net margins, return on equity and return on assets.
此表比較了Alpha Tenowva和ACENTH Life Science的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Teknova | -86.67% | -16.09% | -12.24% |
| Achieve Life Sciences | N/A | -240.36% | -104.96% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 阿爾法·特克諾瓦 | -86.67% | -16.09% | -12.24% |
| 實現生命科學 | 不適用 | -240.36% | -104.96% |
Valuation & Earnings
估值與收益
This table compares Alpha Teknova and Achieve Life Sciences' gross revenue, earnings per share (EPS) and valuation.
下表比較了阿爾法·泰克諾瓦和實現生命科學的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Teknova | $36.89 million | 4.64 | -$9.80 million | ($1.35) | -4.52 |
| Achieve Life Sciences | N/A | N/A | -$33.15 million | ($3.99) | -1.18 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 阿爾法·特克諾瓦 | 3,689萬美元 | 4.64 | -980萬元 | ($1.35) | -4.52 |
| 實現生命科學 | 不適用 | 不適用 | -3,315萬元 | ($3.99) | -1.18 |
Analyst Ratings
分析師評級
This is a breakdown of recent ratings and price targets for Alpha Teknova and Achieve Life Sciences, as provided by MarketBeat.com.
這是由MarketBeat.com提供的阿爾法·特克諾瓦和實現生命科學公司最近的評級和目標價細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Teknova | 0 | 0 | 1 | 0 | 3.00 |
| Achieve Life Sciences | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 阿爾法·特克諾瓦 | 0 | 0 | 1 | 0 | 3.00 |
| 實現生命科學 | 0 | 0 | 2 | 0 | 3.00 |
Alpha Teknova currently has a consensus target price of $9.33, indicating a potential upside of 53.01%. Achieve Life Sciences has a consensus target price of $17.33, indicating a potential upside of 268.01%. Given Achieve Life Sciences' higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Alpha Teknova.
阿爾法·特克諾瓦目前的共識目標價為9.33美元，表明潛在上行空間為53.01%。實現生命科學公司的共識目標價為17.33美元，表明潛在上漲268.01%。考慮到成就生命科學公司更有可能的上行空間，分析師們顯然認為，成就生命科學公司比阿爾法·特克諾瓦更有利。
Institutional and Insider Ownership
機構和內部人持股
22.7% of Alpha Teknova shares are owned by institutional investors. Comparatively, 21.1% of Achieve Life Sciences shares are owned by institutional investors. 15.2% of Alpha Teknova shares are owned by insiders. Comparatively, 1.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Alpha Tenowva 22.7%的股份由機構投資者持有。相比之下，實現生命科學公司21.1%的股份由機構投資者持有。阿爾法公司15.2%的股份由內部人士持有。相比之下，實現生命科學1.0%的股份由內部人士持有。強大的機構持股表明，捐贈基金、大型基金管理公司和對衝基金相信，一家公司有望實現長期增長。
Risk and Volatility
風險和波動性
Alpha Teknova has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
Alpha Tenowva的貝塔係數為0.22，這意味着其股價的波動性比標準普爾500指數低78%。相比之下，實現生命科學的貝塔係數為1.22，這意味着其股價的波動性比標準普爾500指數高22%。
Summary
摘要
Alpha Teknova beats Achieve Life Sciences on 7 of the 12 factors compared between the two stocks.
阿爾法·特克諾瓦在兩隻股票比較的12個因素中有7個超過了實現生命科學。
About Alpha Teknova
關於阿爾法·特克諾瓦
(Get Rating)
(獲取評級)
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
阿爾法·特諾瓦公司為美國和國際上的生命科學市場提供關鍵試劑。它的試劑使生物製藥產品的發現、開發和生產成為可能，如藥物療法、新型疫苗和分子診斷。該公司提供用於細胞生長和克隆的預先澆注的培養基板；用於細胞擴增的液體細胞培養液和補充劑；以及用於樣品處理、再懸浮和純化的分子生物試劑。它服務於生命科學市場，包括製藥和生物技術公司、合同開發和製造組織、體外診斷特許經營權以及學術和政府研究機構。該公司成立於1996年，總部設在加利福尼亞州霍利斯特。
About Achieve Life Sciences
關於實現生命科學
(Get Rating)
(獲取評級)
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
成就生命科學公司是一家臨牀階段的製藥公司，致力於用於戒煙的西替尼克林的開發和商業化。其產品包括胞苷，一種以植物為基礎的生物鹼，與煙鹼型乙酰膽鹼受體具有結合親和力。該公司成立於1991年10月，總部設在加拿大温哥華。
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
接收阿爾法·特克諾瓦日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Alpha Tenowva和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧